1. Conditional Recurrence-Free Survival after Oncologic Extended Resection for Gallbladder Cancer: An International Multicenter Analysis
- Author
-
Yoshikuni Kawaguchi, Felice Giuliante, Wei Qiao, Jean Nicolas Vauthey, Alfredo Guglielmi, Andrea Ruzzenente, M. Piccino, Hop S. Tran Cao, Gregor Duwe, M. Vivanco, Elena Panettieri, Shinji Uemoto, Yun Shin Chun, Eduardo A. Vega, Xabier de Aretxabala, Ching Wei D. Tzeng, Masayuki Okuno, Timothy E. Newhook, Agostino Maria De Rose, Eduardo Vinuela, Mario De Bellis, Hiroto Nishino, and Satoru Seo
- Subjects
medicine.medical_specialty ,Population ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Surgical oncology ,Internal medicine ,medicine ,Hepatectomy ,Humans ,Cholecystectomy ,Stage (cooking) ,Risk factor ,Gallbladder cancer ,education ,Neoplasm Staging ,Retrospective Studies ,education.field_of_study ,business.industry ,Hazard ratio ,medicine.disease ,Confidence interval ,Neoplasm Recurrence ,Oncology ,Local ,030220 oncology & carcinogenesis ,Cohort ,030211 gastroenterology & hepatology ,Surgery ,Gallbladder Neoplasms ,Neoplasm Recurrence, Local ,business - Abstract
Data to guide surveillance following oncologic extended resection (OER) for gallbladder cancer (GBC) are lacking. Conditional recurrence-free survival (C-RFS) can inform surveillance. We aimed to estimate C-RFS and identify factors affecting conditional RFS after OER for GBC. Patients with ≥ T1b GBC who underwent curative-intent surgery in 2000–2018 at four countries were identified. Risk factors for recurrence and RFS were evaluated at initial resection in all patients and at 12 and 24 months after resection in patients remaining recurrence-free. Of the 1071 patients who underwent OER, 484 met the inclusion criteria; 290 (60%) were recurrence-free at 12 months, and 199 (41%) were recurrence-free at 24 months. Median follow-up was 24.5 months for all patients and 47.21 months in survivors at analysis. Five-year RFS rates were 47% for the overall population, 71% for patients recurrence-free at 12 months, and 87% for the patients without recurrence at 24 months. In the entire cohort, the risk of recurrence peaked at 8 months. T3–T4 disease was independently associated with recurrence in all groups: entire cohort [hazard ratio (HR) 2.16, 95% confidence interval (CI) 1.49–3.13, P
- Published
- 2020